Video
Author(s):
Daniel C. Danila, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses choosing among the androgen receptor inhibitors darolutamide (Nubeqa), enzalutamide (Xtandi), and apalutamide (Erleada) when treating patients with castration-resistant prostate cancer.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.